Samir S. Parekh

Hematology | Oncology
10 E 102nd St Fl 6
New York, NY 10029

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 159 publications

Learning from relapse: how MajesTEC-1 immune profiling points the way to next-generation bispecific strategies.

Learning from relapse: how MajesTEC-1 immune profiling points the way to next-generation bispecific strategies.

Journal: Haematologica
Published: July 22, 2026

Spatial multi-omics of multiple myeloma uncovers niche-dependent pro-myeloma and immunosuppressive signaling in the bone marrow and extramedullary lesions.

Spatial multi-omics of multiple myeloma uncovers niche-dependent pro-myeloma and immunosuppressive signaling in the bone marrow and extramedullary lesions.

Journal: bioRxiv : the preprint server for biology
Published: April 03, 2026

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Journal: Haematologica
Published: March 12, 2026

Discovery of a Potent, Selective, and In Vivo Efficacious Covalent Inhibitor for Lysine Methyltransferase SETD8.

Discovery of a Potent, Selective, and In Vivo Efficacious Covalent Inhibitor for Lysine Methyltransferase SETD8.

Journal: Journal of medicinal chemistry
Published: February 16, 2026

Identifying the angiogenic receptor expression in mantle cell lymphoma patients and murine models.

Identifying the angiogenic receptor expression in mantle cell lymphoma patients and murine models.

Journal: Biomarker research
Published: February 13, 2026

Timing and Pattern of Extraosseous Dissemination Are Key Determinants of Survival in Multiple Myeloma.

Timing and Pattern of Extraosseous Dissemination Are Key Determinants of Survival in Multiple Myeloma.

Journal: American journal of hematology
Published: February 09, 2026

Precision Medicine in a Patient With Multiple Myeloma Presenting With t(2;11) and CCND1 Overexpression.

Precision Medicine in a Patient With Multiple Myeloma Presenting With t(2;11) and CCND1 Overexpression.

Journal: EJHaem
Published: January 30, 2026

Baseline absolute lymphocyte count, C-reactive protein, and ferritin predict CAR T cell-related toxicities and outcomes in multiple myeloma.

Baseline absolute lymphocyte count, C-reactive protein, and ferritin predict CAR T cell-related toxicities and outcomes in multiple myeloma.

Journal: Bone marrow transplantation
Published: January 21, 2026

Genomic features of clonal hematopoiesis-associated genes in primary and CAR T-cell-related secondary T-cell malignancies.

Genomic features of clonal hematopoiesis-associated genes in primary and CAR T-cell-related secondary T-cell malignancies.

Journal: Blood neoplasia
Published: January 20, 2026

Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myeloma.

Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myeloma.

Journal: JCI insight
Published: December 23, 2025

Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignancies.

Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignancies.

Journal: Journal for immunotherapy of cancer
Published: November 25, 2025

Environmental exposures and multiple myeloma risk: A contemporary review of epidemiologic associations and mechanistic plausibility.

Environmental exposures and multiple myeloma risk: A contemporary review of epidemiologic associations and mechanistic plausibility.

Journal: Blood reviews
Published: November 24, 2025
Showing 1-12 of 159

Last Updated: 09/26/2026